A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06618001
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06604715
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇪🇸Hosp Univ Fund Jimenez Diaz, Madrid, Spain
🇪🇸Clinica Univ. de Navarra, Pamplona, Spain
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06577025
- Locations
- 🇪🇸
Hosp Clinico Univ de Salamanca, Salamanca, Spain
🇪🇸Hosp. Univ. Marques de Valdecilla, Santander, Spain
🇺🇸City of Hope, Duarte, California, United States
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 752
- Registration Number
- NCT06559306
- Locations
- 🇺🇸
Axiom Research, Colton, California, United States
🇺🇸Excell Research Inc, Oceanside, California, United States
🇺🇸Prospective Research Innovations Inc, Rancho Cucamonga, California, United States
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT06550895
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06532032
- Locations
- 🇨🇳
Changhua Christian Hospital, ChangHua, Taiwan
🇨🇳Chi Mei Medical Center Liu Ying, Liou Ying Township, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT06533098
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 350
- Registration Number
- NCT06514742
- Locations
- 🇺🇸
Elligo Independent Research Sites Mindful Behavioral Health, Boca Raton, Florida, United States
🇺🇸Gulfcoast Medical Research Center, Fort Myers, Florida, United States
🇺🇸Medquest Translational Sciences, Miami Lakes, Florida, United States
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06500884
- Locations
- 🇺🇸
Icahn School of Medicine at Mt. Sinai, New York, New York, United States
🇧🇷Instituto D Or de Pesquisa e Ensino IDOR, Sao Paulo, Brazil
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06470438
- Locations
- 🇨🇳
The First Affiliated Hospital Zhejiang University College of Medicine, Hang Zhou Shi, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Sun Yat-Sen University Cancer Center, Guangzhou, China